Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 5032708, 6 pages
https://doi.org/10.1155/2017/5032708
Clinical Study

Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients

1School of Medicine, Shandong University, Jinan, Shandong, China
2Department of Geriatrics, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China
3Department of MEC, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China
4Department of Nephrology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China
5Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China

Correspondence should be addressed to Shandong Ye

Received 16 December 2016; Accepted 6 February 2017; Published 30 April 2017

Academic Editor: Yunzhou Dong

Copyright © 2017 Xiaojie Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Type 2 diabetes is often associated with arterial atherosclerosis in large blood vessels. We set out to elucidate whether commonly used antidiabetic drugs metformin, sitagliptin, and pioglitazone will reduce atherosclerosis in T2DM patients. We enrolled 176 individuals with type 2 diabetes, which were divided into four treatment groups according to different oral drugs: metformin alone, sitagliptin alone, pioglitazone alone, or combination of metformin and sitagliptin. We assessed changes in glycometabolism, lipid metabolism, cytokine released, and carotid artery intima-media thickness as the readout for improvement in atherosclerosis. HbA1c levels were significantly decreased in all treatment groups (), and FBG levels were also decreased in metformin and combined groups (). In addition, we found IL-6 levels significantly decreased in all treatment groups (). Treatment with pioglitazone showed a significant increase in BMI, HDL, and ADPN levels (). We also observed a significant decrease in NHDL levels in the combined treatment group (). Our data revealed that in addition to hypoglycemic properties of metformin, sitagliptin, and pioglitazone, these drugs also have the potential to promote an anti-inflammatory response. Therefore, combination therapy may be more beneficial for reducing atherosclerosis in patients with type 2 diabetes. The clinical trial is registered with ChiCTR-ORC-17010835.